Form 4: Skye Bioscience Director, Keith Wayne Ward, Acquires 35,000 Stock Options

Keith Wayne Ward, a director at Skye Bioscience, Inc., acquired 35,000 stock options on February 29, 2024, exercisable at $14.56 per share.

Summary

• On February 29, 2024, Keith Wayne Ward, a director of Skye Bioscience, Inc., was granted 35,000 stock options.
• The options are exercisable at a price of $14.56 per share.
• The options vest in equal monthly installments over a one-year period, starting February 29, 2024.
• The options expire on March 1, 2034.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The grant of options to a director is generally viewed as a mildly positive sign, suggesting confidence in the company's future.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of monthly installments over one year is fairly standard.
• The ten-year expiration period is also a common practice.

Key Dates